Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study by Stauder, Reinhard et al.
This is an author produced version of Health-related quality of life in lower-risk MDS 
patients compared with age- and sex-matched reference populations: a European 
LeukemiaNet study.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/128281/
Article:
Stauder, Reinhard, Yu, Ge orcid.org/0000-0002-0891-2501, Koinig, Karin A. et al. (22 more
authors) (2018) Health-related quality of life in lower-risk MDS patients compared with 
age- and sex-matched reference populations: a European LeukemiaNet study. Leukemia : 
official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. ISSN 
1476-5551 
https://doi.org/10.1038/s41375-018-0089-x
promoting access to
White Rose research papers
eprints@whiterose.ac.uk
http://eprints.whiterose.ac.uk/
	

	

			

       

! "#!  $  %#"
" !!&  	! '#


()*(+,+$(#-$$(./%($

#()#
0(123#(#(	24#
'5$( 
 '$#6(  
2 #( +00 7( '"
"2(  "( " )#$(  
2"( 3 2
6( $8 )"-( 	 '9( 1"  ( /5 	""(
%
#( 2-(:
3"&						 	!

	
 	 " #
$ %	& '
	 '	 ($ )	
*+,	 
&
,		-	 '		 &$ ) "
" '. ,/ '/$	 / 0/ 	
	&
 $/ %	 $ '	1-& 2
 	/+	
	 (
 ,3 #/&	 4
	  
(//		!  4$ 1	  	 	 5	 )	+		 6  	  1	+
&
'47	
/7	1	+
	!+/				/	77
(7	,	&	8	

9:::::::::::::::::::::9;<;<=>?
@;=AB+<;>+<<>C+!

 
  4  	   		 7		+	$	1	 
/7  
 		 //	7	  7/
7	 8	 	 7$ 
 	 $	
  	 
/7 
  
	$/	   /
	
 	

/7 1 	 /7	 7	
	   7 	$	1 		  
 7
	  
 
 	
		  	7/7/	

	
	
/$		1//	/ 	
/		
/	
77
	/	$	D;4	/		D<;AEF//	7	=<#D<;>EF
$	
9:::::::::::::::::::::9
©    2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched 1 
reference populations: a European LeukemiaNet study 2 
 3 
Reinhard Stauder* 
1
, Ge Yu
2
, Karin A. Koinig
1
, Tim Bagguley
2
, Pierre Fenaux
3
, Argiris Symeonidis
4
, 4 
Guillermo Sanz
5
, Jaroslav Cermak
6
, Moshe Mittelman
7
, Eva Hellström-Lindberg
8
, Saskia 5 
Langemeijer
9
, Mette Skov Holm
10 ? <ƌǌǇƐǌƚŽĨ DČĚƌǇ11, Luca Malcovati12, Aurelia Tatic13, Ulrich 6 
Germing
14
, Aleksandar Savic
15
, Corine van Marrewijk
9
, Agnès Guerci-Bresler
16
, Elisa Luño
17
, Jackie 7 
Droste
9
, Fabio Efficace
18
, Alex Smith
2
, David Bowen
19
, Theo de Witte
20
 8 
 9 
1 Dep. of Internal Medicine V (Hematology and Oncology), Medical University Innsbruck, Innsbruck, Austria 10 
2 Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, United Kingdom 11 
3 Service d'Hématologie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (AP-HP) and Université Paris 7, Paris, France 12 
4 Dep. of Medicine, Div. Hematology, University of Patras Medical School, Patras, Greece,  13 
5 Dep. Of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain 14 
6 Dep. of Clinical Hematology, Inst. Of Hematology & Blood Transfusion, Praha, Czech Republic 15 
7 Dep. of Medicine A, Tel Aviv Sourasky (Ichilov) Medical Center and Sackler Medical Faculty, Tel Aviv University, Tel Aviv, Israel 16 
8 Dep. of Medicine, Div. Hematology, Karolinska Institutet, Stockholm , Sweden 17 
9 Dep. Of Hematology, Radboud University Medical Center, Nijmegen, Netherlands 18 
10 Dep. of Hematology, Aarhus University Hospital, Aarhus, Denmark  19 
11 Dep. of Hematology, Oncology and Internal Medicine, Warszawa Medical University, Warszawa, Poland 20 
12 Dep. of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy 21 
13 Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania 22 
14 Dep. of Hematology, Oncology and Clinical Immunology, Universitätsklinik Düsseldorf, Düsseldorf, Germany 23 
15 Clinic of Hematology - Clinical Center of Vojvodina, University of Novi Sad, Novi Sad, Serbia 24 
16 Service d'Hématologie, Center Hospitalier Universitaire Brabois Vandoeuvre, Nancy, France 25 
17 Servicio d'Hematología, Servicio de Salud del Principado de Asturias Oviedo, Oviedo, Spain 26 
18 Fondazione GIMEMA Onlus, Rome, Italy 27 
19 St. James's Institute of Oncology, Leeds Teaching Hospitals, Leeds, United Kingdom 28 
20 Dep. of Tumor Immunology - Nijmegen Center for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, 29 
Netherlands 30 
* corresponding author 31 
Corresponding Author 32 
Reinhard STAUDER MD, MSc, Associate Professor  33 
Department of Internal Medicine V (Hematology and Oncology)  34 
Innsbruck Medical University, Anichstraße 35, 6020 Innsbruck, Austria 35 
reinhard.stauder@i-med.ac.at, Tel: 0043 512 504 27302; FAX: 0043 512 504 25615 36 
Running Head: HRQoL in low-risk MDS  37 
Keywords: HRQoL, MDS, EQ-5D, European norms, patient-reported outcome (PRO)  38 
Sources of support: This study was carried out within the EUMDS Registry which is supported by an 39 
educational grant from Novartis Pharmacy B.V. Oncology Europe. This study was supported by Horizon 40 
2020 research and innovation program, grant agreement No 634789, MDS-RIGHT, within Personalising 41 
health and care program PHC-2014-634789. Additionally, this study was supported by Translational 42 
Implementation of genetic evidence in the management of MDS (TRIAGE-MDS) (TRIAGE-MDS, Austrian 43 
Science Found I 1576) within the TRANSCAN - Primary and secondary prevention of cancer call (ERA Net).  44 
©    2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
ABSTRACT 45 
In myelodysplastic syndromes (MDS) health-related quality of life (HRQoL) represents a relevant 46 
patient-reported outcome, which is essential in individualized therapy planning. Prospective data 47 
on HRQoL in lower-risk MDS remain rare. We assessed HRQOL by EQ-5D-questionnaire at initial 48 
diagnosis in 1690 consecutive IPSS-Low/Int-1 MDS-patients from the European LeukemiaNet 49 
Registry. Impairments were compared with age- and sex-matched EuroQol Group norms. A 50 
significant proportion of MDS-patients reported moderate/severe problems in the dimensions 51 
pain/discomfort (49.5%), mobility (41.0%), anxiety/depression (37.9%), and usual activities 52 
(36.1%). Limitations in mobility, self-care, usual activities, pain/discomfort and EQ-VAS were 53 
significantly more frequent in the old, in females, and in those with high co-morbidity burden, low 54 
haemoglobin-levels, or red blood cells transfusion-need (p<0.001). In comparison to age- and sex-55 
matched peers, the proportion of problems in usual activities and anxiety/depression was 56 
significantly higher in MDS-patients (p<0.001). MDS-related restrictions in the dimension mobility 57 
were most prominent in males, and in older people (p<0.001); in anxiety/depression in female and 58 
in younger people (p<0.001); and in EQ-VAS in women and in persons older than 75 years 59 
(p<0.05). Patients newly diagnosed with IPSS lower-risk MDS experience a pronounced reduction 60 
in HRQoL and a clustering of restrictions in distinct dimensions of HRQoL as compared with 61 
reference populations.  62 
  63 
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INTRODUCTION  64 
Myelodysplastic syndromes (MDS) represent challenging hematopoietic disorders characterized by 65 
cytopenias, functional blood defects and clonal hematopoiesis. The clinical course is characterized 66 
by an impaired health-related quality of life (HRQoL), the risk of transformation to acute myeloid 67 
leukaemia (AML) and reduced survival in the majority of patients.
1
 Based on biological parameters, 68 
patients are classified into different risk groups to predict overall survival (OS) and the risk of AML 69 
transformation. The international prognostic scoring system (IPSS)
2
 and more recently, the revised 70 
IPSS (IPSS-R)
3
 represent the gold standard in prognostication of MDS. Based on these scoring 71 
systems, IPSS low/intermediate-1 risk and IPSS-R (very) low/intermediate risk are classified as 72 
lower-risk MDS with a low propensity to transform to AML.
2
 
3
 The treatment goals in this cohort of 73 
patients are an improvement in cytopenias, prolongation of survival, and improvement and 74 
maintenance of HRQoL and functional capacities. IPSS intermediate-2/high and IPSS-R high/very 75 
high risk are classified as higher-risk MDS, which are characterized by an increased risk of AML 76 
transformation and a short median survival of less than two years.
1
 77 
 78 
Patients with MDS often suffer from a high symptom burden, resulting in restrictions in HRQoL. 79 
Assesssment of HRQoL provides information on the patient´s perspective and perception, thus 80 
representing a relevant patient-reported outcome (PRO).
1, 4, 5
 The study of HRQoL has become an 81 
increasingly critical area of research,
6
 as limitations in HRQoL are frequently observed in MDS and 82 
are only partially explained by anaemia.
7, 8
 Moreover, restrictions in HRQoL may predict an 83 
unfavourable clinical outcome.
9-12
 In addition HRQoL represents a parameter of response 84 
evaluation.
1, 13, 14
 Thus, the integration of assessment of HRQoL in MDS has been propagated by 85 
clinicians, stakeholders and authorities.
1, 13-15
 However, definitive data on HRQoL in low-risk MDS 86 
at initial diagnosis are limited by small sample size,
16, 17
 selection bias,
7, 16, 17
 and assessment later 87 
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after initial diagnosis.
7, 11, 16, 18, 19
 In addition, most studies have included patients with higher-risk 88 
MDS,
9-12, 16, 18-20
 AML,
10, 11
 or CMML, 
11, 16
 which precludes precise interpretation. Lower-risk 89 
patients with MDS are typically of advanced age with a median of 74 years at diagnosis.
21
 The 90 
dissection between age-associated restrictions in HRQoL and the incremental impact of MDS in 91 
these patients is relevant, yet has not been analysed at all.  92 
 93 
The main objective of this international prospective cohort observational study is to investigate 94 
the HRQoL-profile of patients with lower-risk MDS at time of diagnosis, as compared with the 95 
general population matched on age and sex. The incremental impact of MDS on symptom burden 96 
is dissected by comparing features in MDS with the general population. A secondary objective is to 97 
examine clinical factors associated with HRQoL of these patients.  98 
 99 
MATERIALS / METHODS  100 
Participants 101 
The EUMDS Registry is a prospective, non-interventional longitudinal study, enrolling newly 102 
diagnosed patients with IPSS low or intermediate-1 MDS from 145 haematology centres in 17 103 
European countries and Israel. Patients with an IPSS risk intermediate-2 or high, or with therapy-104 
related MDS were excluded. Patients without cytogenetic information were only included if the 105 
diagnosis of MDS was morphologically proven, with <5% bone marrow blasts and at most a single 106 
cytopenia according to the IPSS. Based on these criteria, exclusively IPPS low or intermediate-1 107 
patients were included in EUMDS.  108 
 109 
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Therapy is given according to local guidelines.
21
 Enrolment was within 100 days of the diagnostic 110 
bone marrow aspirate. The average time from date of diagnosis to inclusion was 44 days (standard 111 
deviation 28 days). Details on design and data collection have been published elsewhere.
21
 112 
As EQ-5D was not licensed in two countries, 15 countries were included in this analysis. EUMDS 113 
(ClinicalTrials.gov: NCT00600860) has been approved by the ethics committees of all participating 114 
centres and is performed in accordance with the Declaration of Helsinki. Written informed consent 115 
was obtained from all patients. 116 
HRQoL Measurement  117 
Patient reported HRQoL was measured by the European Quality of Life five Dimensions (EQ-5D), at 118 
the time of study enrolment. EQ-5D is a validated, generic, HRQoL-questionnaire,
22
 consisting of 119 
the EQ-5D descriptive system with five dimensions related to daily activities (mobility, self-care, 120 
usual activities, pain/discomfort, anxiety/depression), with three-level answers (no problem, some 121 
problems, severe problems), and a visual analogue scale (EQ-VAS). The five dimensions were 122 
converted into a single summary index (EQ-5D index) by applying the European value set (EVS).
23
 123 
EQ-VAS
22
 ŝƐ Ă ŐůŽďĂů ĞǀĂůƵĂƚŝŽŶ ŽĨ  ?own ŚĞĂůƚŚ ƚŽĚĂǇ ? ƵƐŝŶŐ Ăhealth state scale ranging from 0 124 
(worst imaginable) to 100 (best imaginable). 125 
Measures of Population Norms  126 
The main objective of this paper was to compare the QoL of patients with MDS with general 127 
population with a similar age and gender distribution. Therefore population norms were used as 128 
reference values to assess the relative HRQoL of patients in comparison to that of an average 129 
person.
24
 Population norms are based on descriptions of current health status from population 130 
surveys. Nine European countries in this study (Denmark, France, Germany, Greece, Italy, 131 
Netherlands, Spain, Sweden, and the UK) have reported a series of tables of age/sex population 132 
norms for the EQ-5D for both, profile data and VAS scores.
25
 For the five European countries and 133 
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Israel for which there are no published EQ-5D population norms, we replaced the missing data on 134 
the probabilities of being in a given level for each EQ-5D dimension with the mean of the available 135 
European countries by matching the combination of age group and gender. 136 
Demographic and Clinical Parameters   137 
/ŶĨŽƌŵĂƚŝŽŶ ŽŶ ƉĂƚŝĞŶƚƐ ? ĚĞŵŽŐƌĂƉŚŝĐƐ  ?ĂŐĞ ĂŶĚ ŐĞŶĚĞƌ ?, IPSS-R,co-morbidity index (MDS-CI), 138 
haemoglobin (Hb)-level at the time of diagnosis, and red blood cell transfusions (RBCT) in the year 139 
prior the diagnosis were recorded.
3, 21, 26
 Due to the small number of young adult patients, age was 140 
categorised into three groups (<60, 60 W75, and 75+ years) to compare HRQoL of different age 141 
groups.   142 
Statistical Analysis  143 
Differences in response between the five EQ-5D dimensions in patients with MDS and European 144 
norms were evaluated using chi-square tests. For both EQ-5D index and EQ-VAS, the mean score 145 
ǁŝƚŚƐƚĂŶĚĂƌĚĚĞǀŝĂƚŝŽŶǁĂƐĐĂůĐƵůĂƚĞĚ ?tŝůĐŽǆŽŶ ?ƐƐŝŐŶĞĚƌĂŶŬƐƚĞƐƚƐǁĞƌĞĐŽŶĚƵĐƚĞĚƚŽŝĚĞŶƚŝĨǇ146 
any major difference between the MDS patient baseline values and European norms. The 147 
relationship between HRQoL and demographic/clinical factors was examined using multilevel 148 
linear regression (additional information is available in Supplementary Materials); univariate 149 
analysis was performed for age at diagnosis, gender, IPSS-R, MDS-CI, Hb and RBCT status, and a 150 
multivariate analysis was performed adjusting for all other variables. We assessed the 151 
discriminative ability of HRQoL not only by a significant difference, but also by a minimally 152 
important difference (MID).
27
 The MID is viewed as the smallest difference in score in the domain 153 
of interest that is perceived by patients as beneficial or that would result in a change in treatment. 154 
See supplementary material for more detail.  155 
 156 
All analyses were undertaken in Stata 14 (StataCorp, College Station, TX).  157 
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RESULTS  158 
Characteristics of patients  159 
Based on IPSS-scoring, i.e. the gold-standard in classification at the time at the start of the registry, 160 
1985 patients were included between December 2007 and January 2016, among which 961 161 
(48.4%) were IPSS low-risk and 912 (45.9%) were IPSS Int-1. IPSS score could not be calculated in 162 
5.6% of patients where cytogenetic testing was not available or had failed. Based on inclusion 163 
criteria, exclusively IPSS low or int-1 patients were included. Retrospective classification by IPSS-R 164 
revealed a (very) low risk in 24.8% and 37.6%, an intermediate risk in 21. 2%, high/very high risk in 165 
6.1% and classification was unknown in 10.3% of patients. In total 1690 patients (85.1%) 166 
completed both EQ-5D descriptive system and EQ-VAS. Thirty-three patients (1.7%) completed EQ-167 
5D description only, and 7 patients (0.3%) completed EQ-VAS only (Table 1.). The majority of 168 
patients had advanced age (median age: 74 years), and a male preponderance was observed. 169 
Nearly half of patients were characterized by Hb-levels <10g/dL at baseline, and more than 30% of 170 
patients had received RBCT within one year prior to diagnosis. Demographic characteristics of the 171 
patients who completed EQ-5D did not differ substantially from the total cohort, showing a similar 172 
age distribution and a slightly higher proportion of men. Overall, the HRQoL data in our sample 173 
were likely missing at random (Table 1).   174 
Patients with MDS reveal profound impairments in HRQoL  175 
The MDS-cohort was characterized by a mean EQ-5D index-score of 0.74 and a mean EQ-VAS of 176 
69.6. A significant proportion of MDS-patients reported moderate or severe problems in the 177 
dimensions pain/discomfort (49.5%), mobility (41.0%), anxiety/depression (37.9%), and usual 178 
activities (36.1%), respectively. The dimension with the lowest proportion of restrictions was self-179 
care (13.3%) (Table 2). Clinically meaningful restrictions in the dimensions mobility, self-care, usual 180 
activities, and pain/discomfort as well as in EQ-VAS and EQ-5D index were observed significantly 181 
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more often in older patients and in those with a high co-morbidity burden, low Hb-levels, or RBCT 182 
need (p<0.001). Increased problems with anxiety/depression were significantly more frequent in 183 
women (p<0.001) and in patients with lower Hb-levels (p<0.01). The impact both of IPSS and IPSS-184 
R on EQ-5D scoring was only marginal. In general, restrictions in all parameters of EQ-5D were 185 
significantly more often reported in female patients (p<0.05, Table 2). 186 
Association of restrictions in HRQoL and demographic and disease factors 187 
To assess possible associations between clinical parameters and HRQoL, univariate and 188 
multivariate linear analyses were performed. It was estimated that patients in the reference group 189 
of each of demographic and clinical parameters would have a mean score of 0.85 on the EQ-5D 190 
index, and 80.85 on the EQ-VAS (Table 3). Relative to these scores, there was a significant loss in 191 
HRQL for groups who were older (e.g. 75+ vs <60 years; index: -0.08; VAS: -7.33), female, or had 192 
increased comorbidities, low Hb-levels or transfusion dependence (Table 3.). These differences 193 
exceeded the MID on each of the two HRQL measures (>0.03 on the EQ-5D index and >3.0 on the 194 
EQ-VAS). In summary HRQoL as defined by EQ-5D index and EQ-VAS was more often significantly 195 
impaired in older and in female patients and in persons with advanced comorbidities, low Hb-196 
levels and increased transfusion need both in uni- and in multivariate analyses.  197 
 198 
Comparison of HRQoL in MDS and in age- and sex-matched reference populations  199 
We compared subgroups of MDS-patients with age- and sex-matched reference norms. Overall, 200 
patients with MDS were characterized by a small, but significantly lower EQ-5D index (0.74 vs 201 
0.76) and lower EQ-VAS (69.6 vs 71.8) than European norms (p<0.05)(Table 4). However, these 202 
differences were too small to fulfil the criteria of MID. In contrast distinct differences which 203 
fulfilled the criteria of a MID were seen in individual components of EQ-5D: a significantly higher 204 
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proportion of MDS-patients reported moderate/severe problems in the dimensions mobility, usual 205 
activities and anxiety/depression compared to the reference populations (p<0.001)(Table 4).  206 
 207 
Analyses stratified by sex and age depicted most pronounced differences in the dimensions 208 
anxiety/depression, and usual activities, in all age groups, and in both sexes (p<0.001). Compared 209 
to peers, prevalence of problems in anxiety/depression was most prominent in female (16.7 vs. 210 
50.3%; Fig. 1B), and in younger patients (9.8 vs. 40.8%, p<0.001; Fig. 2A). Restrictions in mobility 211 
were most pronounced in male (Fig. 1A), and in older patients (60+ years; p<0.01; Fig. 2C). The 212 
dimensions self-care and pain/discomfort were not different between the cohorts (Table 2; Figure 213 
1 & 2). Differences in EQ-5D index were most pronounced in younger MDS-patients (<60yrs). EQ-214 
VAS was more often diminished at advanced age (75+ yrs) as compared to peers (p<0.001; Table 215 
2). These differences fulfilled the criteria of a MID.  216 
 217 
DISCUSSION  218 
This prospective cohort observational study adds substantial information on the prevalence and 219 
clustering of restrictions in HRQoL in lower-risk Patients with MDS at diagnosis. In a cross-sectional 220 
analysis, we observed profound restrictions in distinct dimensions of the EQ-5D when compared 221 
with European reference populations. Moreover, we identified demographic and clinical factors, 222 
which are associated with restrictions in HRQoL.  223 
Prevalence of restrictions in HRQoL in MDS at initial diagnosis / Factors associated with 224 
decreased HRQoL  225 
Data on symptom burden in lower-risk MDS at initial presentation are rare, and limited by small 226 
sample size,
16, 17
 selection bias,
7, 16, 17
 and analyses performed later after initial diagnosis.
7, 11, 16, 18, 227 
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19
 In addition, most studies have included patients with higher risk MDS,
9-11
 
9-11, 16, 18-20
, AML
10, 11
 or 228 
CMML 
11, 16
, which precludes precise interpretation. The strength of our study is the large number 229 
of observations at initial diagnosis and the parallel analysis of the different parameters of the 230 
validated score EQ-5D including EQ-5D VAS, EQ-5D index as well as the different EQ-5D 231 
dimensions in a homogenous cohort of lower-risk patients. This is the first report to present 232 
details on restrictions in the distinct domains of EQ-5D in MDS, which reveals huge differences in 233 
HRQoL-profile in daily activities. These findings are particularly relevant, as studies from the 234 
literature reported exclusively EQ-5D summary scores and EQ-5D VAS,
16, 20
 but lacked a 235 
presentation of EQ-5D daily activities.  236 
 237 
Our study shows a pronounced symptom burden in many patients with MDS, predominantly in the 238 
dimensions pain/discomfort, mobility, anxiety/depression, and usual activities. Moreover, a 239 
clustering of symptoms in distinct subgroups of patients is revealed. The low percentage of self-240 
reported problems in the dimension self-care, particularly in elderly is remarkable. This 241 
phenomenon has been observed across different cancer types 
28
 and may be explained by focusing 242 
on  ?ǁĂƐŚŝŶŐĂŶĚĚƌĞƐƐŝŶŐ ? in the definition of self-care, whereas functional capacities like  ?ǁŽƌŬ ?243 
housework, family or leisure activities ?are assessed in the dimension  ?ƵƐƵĂůĂĐƚŝǀŝƚŝĞƐ ? ? 244 
 245 
We demonstrated that advanced age, pronounced co-morbidities, low Hb-levels, RBCT need, and 246 
female sex, were significantly associated both with a decreased EQ-5D index, and decreased EQ-247 
VAS after adjustment for co-variables. These observations extend data from the literature 
7, 8, 18, 20
 248 
and define cohorts of patients which are at high risk of decreased HRQoL. Hb-levels 
7, 18, 20
 and 249 
transfusion dependence
20
 are important predictors of HRQoL, both in this study and in the 250 
literature. Effective treatment for anemia and reduction of transfusion need might thus contribute 251 
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to improvement and maintenance of HRQoL.
17
 Future studies will focus on the prediction of 252 
deterioration of HRQoL, and focus on early prevention. 253 
 254 
A relevant aspect of our work is the significant difference in symptom burden in patients with MDS 255 
as compared to age- and sex matched European reference populations. Thus, dissection of 256 
features which are MDS-specific from symptoms which are present in matched general 257 
populations is possible. This study reveals an incremental symptom burden in MDS characterized 258 
by pronounced age- and sex-dependent differences in the distinct EQ-5D dimensions. Both young 259 
and old patients suffer from troublesome MDS-related symptoms. Data from the literature are 260 
rare and have been characterized by a small sample size and were restricted to one country.
16, 17
 261 
The study of Hellstrom evaluated HRQoL at later time points after diagnosis, and was focused on 262 
selecting anaemic patients with a high probability for response to ESAs for a clinical study.
17
 The 263 
study of Jansen
16
 reported exclusively EQ-5D VAS but lacked a presentation of EQ-5D daily 264 
activities for which we show strong differences. Moreover, patients in Jansen´s study were 265 
entered at variable time points after diagnosis, and included patients with higher risk MDS and 266 
CMML.
16
  267 
 268 
The high prevalence of anxiety/depression and of limitations in usual activities is more 269 
pronounced in women in our study. These observations form the basis to appreciate the relevance 270 
of MDS on individual health in a given patient and the opportunity to assist health care providers 271 
in managing the relevant symptoms.
8
 Thus, patient-centred care will be improved by special 272 
attention to patient subgroups.
29, 30
 The finding of the difference of depression between our MDS 273 
patients and the general population is corroborated by similar evidence in other hematologic 274 
conditions. For example, Efficace et al.
31
 observed that depression was one of the most impaired 275 
psychological domains in a sample of chronic myeloid leukemia patients as compared to their 276 
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peers in the general population; and, similar to our findings, this impairment was most 277 
pronounced in female patients. In agreement with other studies,
8, 32, 33
 differences by gender were 278 
observed with lower HRQoL being more pronounced in females. Although the discussion of causes 279 
of disparity in gender-based distribution is beyond the scope of this manuscript, gender-specific 280 
evaluations and interventions should be discussed or suggested in patients with MDS.  281 
 282 
The relevance of anxiety/depression in patients with MDS is supported by the fact that 9.5% of EU-283 
MDS patients receive antidepressants at baseline,
21
 and that impairments in depression screening 284 
by geriatric depression scale (GDS) are observed in 24% of patients with MDS
34
. Likewise 285 
 ?ĞŵŽƚŝŽŶĂůŚĞĂůƚŚ ?ĂŶĚ  ?ƵŶĐĞƌƚĂŝŶƚǇ ?ƐĞŶƐĞŽĨĐŽŶƚƌŽů ?have been highly ranked by patients and 286 
caregivers in a recent study.
35
 To address the individual needs of patients with MDS, the novel, 287 
disease specific score for MDS, QUALMS,
18, 35
 is currently applied and validated in the EUMDS-288 
cohort. Our study also confirms that age- and sex-dependent baseline values in HRQoL should be 289 
considered when interpreting the results of clinical studies in MDS that use HRQoL as an endpoint, 290 
as suggested recently.
4, 8
 291 
 292 
Strengths of this work are the large number of observations, the well-defined inclusion criteria in a 293 
non-interventional registry, the enclosure of newly diagnosed MDS-patients within 100 days of the 294 
date of the diagnostic bone marrow aspirate, and the parallel analysis of the different parameters 295 
of the validated generic score EQ-5D.
21 
Based on the use of a generic questionnaire, comparisons 296 
with reference populations are possible.  297 
Limitations: Disease-specific scores may more accurately reflect the spectrum in a given disease. 298 
To address this aspect, the MDS-specific score QUALMS has been developed recently.
18, 35
 299 
QUALMS has been integrated in EUMDS in a recently amended version of the protocol. Based on 300 
objectives of this study and the EUMDS-registry, analyses have been restricted to IPSS lower-risk 301 
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MDS. Therefore, this study does not allow conclusions on MDS in general.  However, the recently 302 
introduced new protocol of the registry will register all subtypes of MDS. Other aspects of HRQoL, 303 
which might be relevant for the outcome of patients e.g. the deterioration of HRQoL over time, 304 
have not yet been analysed. These investigations are currently performed in several studies 305 
focusing on the impact of specific interventions on HRQoL.  306 
In summary 307 
This is the first study to analyse prospectively the patient reported outcome HRQoL in IPSS lower-308 
risk MDS at diagnosis, and to compare patients with MDS with age- and sex matched healthy 309 
populations. Patients experience profound age- and sex-dependent restrictions in different 310 
HRQoL-dimensions. Distinct demographic and disease parameters are associated with reduced 311 
HRQoL. These observations should form the basis for individualized treatment directed at relief of 312 
distinct symptoms. In addition, these results may provide a benchmark in the evaluation of new 313 
interventional options aimed at improving HRQoL outcomes. 314 
 315 
 316 
Supplementary information is available at Leukemia (www.nature.com/leu) providing additional 317 
information regarding (i) EQ-5D index and EVS; (ii) on the comparison of patients with MDS and 318 
the reference population; (iii) on multivariate analysis;  and (iiii) on minimally important difference 319 
(MID) 320 
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Figure Legends 
Fig 1: Proportion of moderate/severe problems in male (A) and female (B) patients with MDS (blue bars) as 
compared to European age- and sex matched standard population (dark grey). Standard errors indicated as 
OLQHV 'LIIHUHQFHV ¨ RI SDWLHQWV ZLWK 0'6 WR VH[-matched reference group shown when significant 
(*** p<0.001; ** p<0.01; * p<0.05; as assessed by Wilcoxon signed rank tests). 
Fig 2: Proportion of moderate/severe problems by age group (<60 (A), 60-75 (B) or >75 (C) years old) in 
patients with MDS (blue bars) as compared to European age- and sex matched standard population (dark 
JUH\ 6WDQGDUG HUURUV LQGLFDWHG DV OLQHV 'LIIHUHQFHV ¨ RI SDWLHQWV ZLWK 0'6 WR VH[-matched reference 
group shown when significant (*** p<0.001; ** p<0.01; * p<0.05; as assessed by Wilcoxon signed rank 
tests). 
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  Table 1. Demographic and clinical characteristics of MDS-patients - entire cohort and EQ-5D respondents   
  
  Total    EQ-5D Completedi   EQ-5D Not completed   
  
Characteristic  No. of Patients %   No. of Patients %   No. of Patients %   
  Entire Cohort 1 985 100.0 
 
1 690 85.1 
 
295 14.9   
  Age, years                   
  <60 214 10.8   187 11.1   27 9.2   
  60-75 818 41.2   707 41.8   111 37.6   
  75+ 953 48.0   796 47.1   157 53.2   
  Gender 
        
  
  Male 1 202 60.6 
 
1 039 61.5 
 
163 55.3   
  Female 783 39.4 
 
651 38.5 
 
132 44.7   
  Diagnosis (WHO 2001)                   
  RA 355 17.9   283 16.7   72 24.4   
  RARS 310 15.6   276 16.3   34 11.5   
  RCMD 755 38.0   651 38.5   104 35.3   
  RCMD-RS 118 5.9   102 6.0   16 5.4   
  RAEB-1 239 12.0   207 12.2   32 10.8   
  RAEB-2 9 0.5   8 0.5   1 0.3   
  MDS-U 81 4.1   68 4.0   13 4.4   
  5q-Syndrome 118 5.9   95 5.6   23 7.8   
 IPSS          
 Low risk 961 48.4  813 48.1  148 50.3  
 Intermediate-1 912 45.9  782 46.3  130 43.9  
 Low/int-1 no cytogenetics* 112 5.6  95 5.6  17 5.7  
  IPSS-R 
        
  
  Very low risk 493 24.8 
 
433 25.6 
 
60 20.3   
  Low risk 746 37.6 
 
646 38.2 
 
100 33.9   
  Intermediate risk 420 21.2 
 
341 20.2 
 
79 26.8   
  High/very high risk 121 6.1 
 
110 6.5 
 
11 3.7   
  Unknown 205 10.3 
 
160 9.5 
 
45 15.3   
  MDS-CI                   
  Low risk 1 276 64.3   1 076 63.7   200 67.8   
  Intermediate risk 606 30.5   525 31.1   81 27.5   
  High risk 103 5.2   89 5.3   14 4.7   
  Hemoglobin (g/dL)                   
  >=10 1 076 54.2   913 54.0   163 55.3   
  <10 884 44.5   768 45.4   116 39.3   
  Unknown 25 1.3   9 0.5   16 5.4   
  Red Blood Cell Transfusion  # 
        
  
  No 1 390 70.0 
 
1 163 68.8 
 
227 76.9   
  Yes 595 30.0 
 
527 31.2 
 
68 23.1   
©    2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
  
Abbreviations: WHO, World Health Organization; IPSS International Prognostic Scoring System, IPSS-R, Revised International Prognostic Scoring 
System; MDS-CI, Myelodysplastic Syndrome-Comorbidity Index; HCT-CI, Hematopoietic Cell Transplant-Comorbidity Index.  
i Includes EQ-5D completed only, EQ VAS completed only and both completed. 
* Patients with cytogenetics failed or not available were included if the diagnosis of MDS was morphologically proven, with <5% bone marrow blasts 
and at most a single cytopenia according to the IPSS. Based on these criteria exclusively IPPS low or int-1 patients were included in this cohort. 
# as assessed in the year prior to initial diagnosis   
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  Table 2. Prevalence of problems in distinct dimensions of EQ-5D, in EQ-5D index and in EQ VA
  
 
Mobility 
 
Self-care 
 
Usual Activities 
 
Pain/Discomfort 
 
Anxiety/Depression 
 
EQ
  
 
Problemi 
 
Problemi 
 
Problemi 
 
Problemi 
 
Problemi 
 
  
  
  % p   % p   % p   % p   % p 
 
mean SD
 Total  41.0 
 
 13.3 
 
 36.1 
 
 49.5 
 
 37.9 
 
 0.74 0
 
  
 
  
 
  
 
  
 
  
 
  
  Sex   0.007     0.030     0.021     <0.001     <0.001     
  Male 39.1     11.6     33.6     45.5     30.1     0.77 0
  Female 44.0     16.0     40.0     55.9     50.3     0.69 0
  Age Group (years)   <0.001     <0.001     <0.001     <0.001     0.581     
  <60 18.5     2.7     26.6     31.5     40.8     0.80 0
  60-75 33.0     8.5     29.1     43.5     35.9     0.78 0
  75+ 53.3     20.0     44.5     58.9     39.0     0.69 0
  IPSS   0.083     0.057     0.899     0.005     0.884     
  Low risk 42.4     13.2     49.6     53.1     39.2     0.74 0
  Intermediate risk 38.2     13.1     47.7     49.3     36.8     0.75 0
  Low/int-1 no cytogenetics* 51.6     16.1     64.5     44.7     36.6     0.70 0
  IPSS-R   0.656     0.907     0.899     0.023     0.119     
  Very low risk 40.6     11.9     32.4     53.1     33.8     0.75 0
  Low risk 40.8     13.0     36.6     49.3     38.9     0.73 0
  Intermediate risk 42.4     14.4     36.5     44.7     42.9     0.73 0
  High/very high risk 40.4     14.7     35.8     52.3     36.7     0.76 0
  Unknown 40.6     15.0     43.1     48.8     35.0     0.74 0
  MDS-CI   <0.001     <0.001     <0.001     <0.001     0.493     
  Low risk 33.9     10.1     31.6     44.5     37.3     0.76 0
  Intermediate risk 51.8     18.4     42.8     57.2     38.4     0.70 0
  High risk 63.6     22.7     50.0     64.8     42.0     0.67 0
  Haemoglobin (g/dL)   <0.001     <0.001     <0.001     0.026     0.002     
  >=10 34.5     9.2     28.9     46.9     34.3     0.77 0
  <10 49.2     18.3     45.0     53.2     42.4     0.70 0
  Unknown 0.0     0.0     0.0     0.0     22.2     0.95 0
  Red Blood Cell Transfusion #   <0.001     <0.001     <0.001     0.049     0.070     
  No 35.9     9.8     30.9     47.5     36.2     0.76 0
  Yes 52.2     21.0     47.4     53.9     41.7     0.69 0
  
Abbreviations: IPSS-R, Revised International Prognostic Scoring System; MDS-CI, Myelodysplastic Syndrome-Comorbidity Index;.i Problem: moderate or severe 
* Patients with cytogenetics failed or not available were included if the diagnosis of MDS was morphologically proven, with <5% bone marrow blasts and at most a sin
exclusively IPPS low or int-1 patients were included in EUMDS. 
 
 
 
 
©    2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
  
 
 
  
Table 3. Association of HRQL and demographic and disease characteristics in MDS-patients based on univariate and mul
  
  EQ-5D Index (n = 1,681 patients)   
  
 
Univariate 
 
Multivariate * 
 
Univariate
  
Variable  coef. 95% CI p   coef. 95% CI p   coef. 95% CI 
  Constant 0.74 0.73 0.76 <0.001 
 
0.85 0.81 0.89 <0.001 
 
70.71 67.98 
  Age Group                         
  <60                         
  60-75 -0.03 -0.06 0.01 0.144   -0.02 -0.05 0.02 0.287   -3.12 -6.23 
  75+ -0.11 -0.14 -0.07 <0.001   -0.08 -0.12 -0.05 <0.001   -10.06 -13.19 
  Sex 
            
  Male 
            
  Female -0.07 -0.09 -0.05 <0.001 
 
-0.08 -0.10 -0.06 <0.001 
 
-3.24 -5.17 
  IPSS-R                         
  Very low risk                         
  Low risk -0.01 -0.04 0.02 0.414   0.03 0.00 0.06 0.045   -2.19 -4.59 
  Intermediate/high risk -0.01 -0.04 0.03 0.750   0.04 0.01 0.07 0.022   -2.68 -5.42 
  Unknown 0.00 -0.04 0.04 0.909   0.02 -0.02 0.07 0.254   -0.01 -3.69 
  MDS-CI 
            
  Low risk 
            
  Intermediate/high risk -0.07 -0.09 -0.04 <0.001 
 
-0.06 -0.08 -0.04 <0.001 
 
-7.33 -9.26 
  Hemoglobin (g/dL)                         
  >=10                 
  
      
  <10 -0.07 -0.09 -0.04 <0.001   -0.05 -0.08 -0.03 <0.001   -7.12 -8.99 
  Red Blood Cell Transfusion # 
            
  No 
            
  Yes -0.07 -0.10 -0.05 <0.001   -0.04 -0.07 -0.02 <0.001   -7.14 -9.14 
  
Abbreviations: IPSS-R, Revised International Prognostic Scoring System; MDS-CI, Myelodysplastic Syndrome-Comorbidity Index.  
# as assessed in the year prior to initial diagnosis;  * adjusted for all other variables  
 
 
 
 
 
 
©    2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
  
  
Table 4. Comparison of HRQL in MDS-patients and age and sex matched European refere
      Mobility   Self-care   Usual Activities   Pain/Discomfort   Anxiety/Depression   EQ-
  
  
Problemi 
 
Problemi 
 
Problemi 
 
Problemi 
 
Problemi 
 
  
      % p   % p   % p   % p   % p   mean 
  Entire Cohort     <0.001     0.438     <0.001     0.919     <0.001     
  European Norm   33.5     12.4     26.0     48.8     14.9     0.76 
  EUMDS   41.0     13.3     36.1     49.5     37.9     0.74 
  Male     <0.001     0.409     <0.001     0.371     <0.001     
  European Norm   29.4     10.7     23.4     43.9     13.7     0.79 
  EUMDS   39.1     11.6     33.6     45.5     30.1     0.77 
  
                  
  Female     0.142     0.820     <0.001     0.355     <0.001     
  European Norm   40.0     15.0     30.1     56.8     16.7     0.72 
  EUMDS   44.0     16.0     40.0     55.9     50.3     0.69 
    
                 
  Age Group, <60 
  
0.202 
  
0.288 
  
<0.001 
  
0.645 
  
<0.001 
  
  European Norm 
 
13.6 
  
4.9 
  
11.4 
  
28.3 
  
9.8 
 
 
0.86 
  EUMDS 
 
18.5 
  
2.7 
  
26.6 
  
31.5 
  
40.8 
  
0.80 
  
                  
  Age Group, 60-75      0.002     0.179     <0.001     0.606     <0.001     
  European Norm   25.4     6.7     20.0     44.5     14.9     0.79 
  EUMDS   33.0     8.5     29.1     43.5     35.9     0.78 
  
                  
  Age Group, 75+  
  
<0.001 
  
0.711 
  
<0.001 
  
0.671 
  
<0.001 
  
  European Norm 
 
45.2 
  
19.1 
  
34.6 
  
57.4 
  
16.0 
  
0.71 
  EUMDS   53.3     20.0     44.5     58.9     39.0     0.69 
  
i Problem: moderate or severe problems 
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